Tawanda Gumbo

This study evaluates sulbactam-durlobactam plus ceftriaxone dosing and combination regimens for Mycobacterium abscessus lung disease, finding that sulbactam-durlobactam-ceftriaxone achieves the highest microbial kill in a hollow fiber model.

The paper evaluates new drug regimens for Mycobacterium avium lung disease using an in vitro model and basis functions, finding that ceftriaxone-omadacycline-rifabutin outperforms the standard-of-care.

The paper evaluates tigecycline pharmacodynamics in MAC lung disease using time-kill studies and hollow fiber systems, finding EC50 values and suggesting inhaled tigecycline as a potential treatment.

The paper benchmarks preclinical tools for Mycobacterium avium lung disease drug development, finding significant variability in PK/PD target attainment and recommending HFS-MAC for antibiotic ranking and translational studies.